BREAKING: Amgen Ending 340B-Like Price Reductions on Orphan Drugs on Jan. 1 (Updated)

Biopharmaceutical company Amgen is ending voluntary 340B pricing on orphan drugs for certain 340B hospital covered entities effective Jan. 1. | Source: Shutterstock

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.